Biotech entity
Every one of those 1 sits in a single category, pharma. Die Chirurgie is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Die Chirurgie is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. Their average consequence score of 6 runs above the beat's 5.7 for that window. We currently track 1 Biotech story that mention PICO7, all published on August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PICO7. Shared-story counts are live from our verified record — not editorial picks.
German expert panel validates single-use NPWT for surgical incisions, reinforcing the economic case for Smith & Nephew's PICO7. The guidance, published in Die Chirurgie, emphasizes reduced hospital stays and complication costs, a potential tailwind for device adoption in the EU's largest market.
Source: manilatimes.net · finanznachrichten.de
PICO7 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
